[2]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin., 2020, 70(1), 7-30.
[3]
Birudukota, N.; Mudgal, M.M.; Shanbhag, V. Discovery and development of azasteroids as anticancer agents. Steroids, 2019, 152e108505
[4]
Pulte, D.; Weberpals, J.; Jansen, L.; Brenner, H. Changes in population-level survival for advanced solid malignancies with new treatment options in the second decade of the 21st century. Cancer, 2019, 125(15), 2656-2665.
[5]
Kerru, N.; Singh, P.; Koornanally, N.; Raj, R.; Kumar, V. Recent advances (2015-2016) in anticancer hybrids. Eur. J. Med. Chem., 2017, 142, 179-212.
[6]
Dallavalle, S.; Dobricic, V.; Lazzarato, L.; Gazzano, E.; Machuqueiro, M.; Pajeva, I.; Tsakovska, I.; Zidar, Z.; Fruttero, R. Improvement of conventional
anti-cancer drugs as new tools against multidrug resistant tumors. Drug Resist. Update., 2020, 50e100682
[7]
Dong, J.; Zhang, Q.; Wang, Z.; Huang, G.; Li, S. Recent advances in the development of indazole-based anticancer agents. ChemMedChem, 2018, 13(15), 1490-1507.
[8]
Dadashpour, S.; Emami, S. Indole in the target-based design of anticancer agents: A versatile scaffold with diverse mechanisms. Eur. J. Med. Chem., 2018, 150, 9-29.